Relapse Prevention With Varenicline (0815)
|ClinicalTrials.gov Identifier: NCT00944554|
Recruitment Status : Completed
First Posted : July 23, 2009
Results First Posted : June 23, 2017
Last Update Posted : August 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Recurrence Smoking Cessation Substance-Related Disorders||Drug: Varenicline Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||104 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Relapse Prevention With Varenicline|
|Study Start Date :||October 2008|
|Primary Completion Date :||May 2011|
|Study Completion Date :||May 2011|
Placebo Comparator: Placebo
Group given placebo.
Placebo given twice a day or five weeks.
Experimental group given varenicline dosing.
Varenicline given twice a day or five weeks.
Other Name: Varenicline (Chantix®)
- Days to Relapse [ Time Frame: 4 weeks ]Number of days following the programmed lapse exposure until relapse to smoking occurred
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00944554
|United States, Maryland|
|Behavioral Pharmacology Research Unit|
|Baltimore, Maryland, United States, 21224|
|Principal Investigator:||Maxine L Stitzer, PhD||Johns Hopkins University|